The pharmacokinetics of cerivastatin in patients on chronic hemodialysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 5, 2001, Pages 192-198

  Muck W ^a   Park, S ^a   Jager W ^a   Voith, B ^a   Wandel, E ^a   Galle, P R ^a   Schwarting, A ^a  

^a BAYER AG   (Germany)

Author keywords

Cerivastatin; CoA reductase inhibitor; Hemodialysis; HMG; Renal disease

Indexed keywords

CERIVASTATIN; CHOLESTEROL; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FLUORESCENCE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; MEASUREMENT; PARAMETER; PREDICTION; STEADY STATE; TIME;

EID: 0035047223     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39192     Document Type: Article

References (17)

1. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
2. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
3. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes a possible protective mechanism against atherothrombosis
4. The pharmacokinetics of pravastatin in patients on chronic hemodialysis
5. Analysis of cardiovascular risk factor in chronic hemodialysis patients with special attention to the hyperlipoproteinemias
6. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
7. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures
8. Lipids and the kidney
9. LC separation and induced fluorometric detection of rivastatin in blood plasma
10. Cerivastatin (BAY w 6228): A novel HMG-CoA reductase inhibitor
11. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults
12. Clinical pharmacokinetics of cerivastatin
13. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
14. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects
15. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
16. A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidemia
17. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance